• Parabilis Medicines director Alan Sebulsky reported purchases of 17,500 common shares at weighted-average prices of USD 25.9978 to USD 27.6696.
• Holdings reported as indirectly owned through Apothecary Capital LLC rose to 30,000 common shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Parabilis Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-273013), on June 16, 2026, and is solely responsible for the information contained therein.